TET2 and heart disorder: Worth noting, a recent study in TET2-mutant patients treated with IL-1β inhibitor canakinumab reports decreased cardiovascular events in these patients, highlighting the potential involvement of TET2 mutations in cardiac disease via inflammatory pathways, as well as the therapeutic role of targeting inflammation [44,132].